Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

Q4 2024 Earnings Call Transcript February 26, 2025 Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is ...

Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...

Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Sanofi has a 52-week low of $45.22 and a 52 ... neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established ...

Sanofi’s type 2 diabetes combination drug Suliqua has been approved in Europe – setting the scene for a showdown with Novo Nordisk’s rival, Xultophy. The EU approval means Sanofi and Novo ...

Dr. Debasish Roychowdhury, senior vice president and head of Sanofi Oncology. "It is currently hard to tackle ovarian cancer. There are very few drugs available. We are very happy to collaborate ...

In-person registration is now SOLD OUT. Join us for Advancing the Cardiovascular Care of the Oncology Patient virtually to reconnect with your peers, and the faculty. Advancing the Cardiovascular Care ...